CRISPR Therapeutics enters collaboration with Sirius on FXI-targeting siRNA; positive Phase 1 data

CRISPR Therapeutics AG

Upfront consideration: $70M in common shares + $25M cash to Sirius for co-development of FXI-targeting siRNA SRSD107.
Potential milestones: up to $340M for opt-out and up to $87.5M for development/regulatory; royalties mid-single to low-double digit.
Phase 1: single doses well tolerated, >93% reduction in FXI levels and activity, sustained up to six months post-dosing.
Phase 2 trial initiated for prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Company has options to exclusively license Sirius siRNA technology for up to two additional targets; $10M option fee per target.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.